B 6107Alternative Names: B6107
Latest Information Update: 03 Mar 2016
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified
Most Recent Events
- 02 Mar 2016 Early research in Undefined indication in South Korea (PO) before March 2016